Alzheimers sjukdom biomarkörer för molekylära mekanismer, diagnostik och theragnostik. Alzheimer's disease - biomarkers for molecular mechanisms, diagnostics and theragnostics
The Swedish Brain Foundation
We have developed an efficient strategy to identify novel biomarkers by targeted proteomics, develop novel immunoassays or MS based assays, make a thorough neurochemical validation of the biomarker and finally validate their clinical and pathogenic performance. We also have a long lasting experience in transferring biomarker assays to clinical routine and implement them in clinical trials. Thus, we are very optimistic that this project will result in novel valuable biomarkers for AD. In future clinical routine, novel CSF biomarkers for the central pathologies together with knowledge on the temporal sequence of pathologic events will also facilitate the selection of individuals that will be most likely to
respond to a new disease-modifying therapy directed against a specific pathology. Blood biomarkers will be highly valuable as screening tools in primary care, to allow selection of patients for admission to the specialist clinic.